What is the size of the Global Point of Care Testing for Rheumatoid Arthritis Market?

Global Point of Care Testing for Rheumatoid Arthritis Market is estimated to be USD 1.2 Billion in 2022 and is estimated to reach a value of USD 2.05 Billion by 2030, growing at a CAGR of 6.5 % during the forecast period of 2023 – 2030.

What are the segments under the Global Point of Care Testing for Rheumatoid Arthritis Market by Technology?

. Based on Technology, the Global Point of Care Testing for Rheumatoid Arthritis Market is segmented into Immunoassays, Biosensors, Dipsticks, Molecular Diagnostics, and others.

Which is the most dominant country in the region of North America for Point of Care Testing for Rheumatoid Arthritis?

The United States of America is the most dominant country in the region of North America for Point of Care Testing for Rheumatoid Arthritis

Who are the leading market players in the Global Point of Care Testing for Rheumatoid Arthritis Market?

Abbott Diagnostics, F. Hoffman-la Roche Ltd., Seimens AG, Augurex Life Science Corp., Sysmex Corporation, Thermo Fisher Scientific Inc., Beckman Coulter Inc., Labcorp, Qiagen, Novo Integrated Science Inc.

Global Point of Care Testing for Rheumatoid Arthritis Market | Size, overview, trends, and Forecast

Q: What are the Global Point of Care Testing for Rheumatoid Arthritis Market Drivers?

. The increase in rheumatoid arthritis among the geriatric population and research and innovation in Point of Care Testing technology are the market drivers